Medifast, Inc.
MED
$11.48
$0.000.00%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -34.03% | -36.31% | -35.96% | -36.29% | -37.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.03% | -36.31% | -35.96% | -36.29% | -37.62% |
| Cost of Revenue | -22.43% | -27.12% | -29.93% | -32.98% | -37.39% |
| Gross Profit | -38.14% | -39.56% | -38.11% | -37.47% | -37.70% |
| SG&A Expenses | -29.66% | -34.00% | -32.62% | -37.63% | -36.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.56% | -32.15% | -31.87% | -36.28% | -36.48% |
| Operating Income | -266.99% | -398.25% | -192.40% | -37.29% | -62.07% |
| Income Before Tax | -323.39% | -11.47% | -248.84% | -83.61% | -83.23% |
| Income Tax Expenses | 344.61% | 4,433.45% | 668.51% | -64.50% | -67.13% |
| Earnings from Continuing Operations | -803.74% | -186.19% | -992.54% | -96.61% | -87.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -803.74% | -186.19% | -992.54% | -96.61% | -87.60% |
| EBIT | -266.99% | -398.25% | -192.40% | -37.29% | -62.07% |
| EBITDA | -129.39% | -121.07% | -99.89% | -12.47% | -43.62% |
| EPS Basic | -801.48% | -184.77% | -979.45% | -96.65% | -87.70% |
| Normalized Basic EPS | -188.28% | -321.44% | -138.21% | 12.17% | -51.65% |
| EPS Diluted | -829.90% | -181.48% | -1,049.97% | -98.57% | -88.07% |
| Normalized Diluted EPS | -188.67% | -324.82% | -138.58% | 12.43% | -51.62% |
| Average Basic Shares Outstanding | 0.71% | 0.50% | 0.46% | 0.44% | 0.42% |
| Average Diluted Shares Outstanding | 0.37% | 0.48% | 0.32% | 0.41% | 0.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -1.12% | 0.85% | -1.03% | -0.69% | -0.96% |